On August 27, 2018, the SungenBio Scientists Forum and the Inauguration Ceremony of the Anti-Suppository and Thrombolytic Innovative Drug Research Center was held at the Xiamen International Convention and Exhibition Center. More than 200 experts and scholars from the medical and scientific fields, as well as SungenBio-Partners and media from all walks of life attended the conference.

SungenBio and Shenyang Pharmaceutical University jointly established the Anti-Thrombolytic and Thrombolytic Innovative Drug Research Center, which will establish a three-level prevention system and a prevention and treatment technology platform for the prevention and treatment of anti-coagulant drugs and thrombolytic drugs through the two-way combination of SungenBio and Shenyang Pharmaceutical University's scientific research elites and professional R&D technology. At the same time, the Thrombosis Prevention Science Education Fund was established to carry out popular science education on prevention and treatment of thrombosis and vascular diseases, and to provide medical assistance to patients suffering from thrombosis and vascular diseases. According to Dr. Chen Jiepeng from Shuangjun Biological, the center will overcome the difficulties in research and development of oral administration of hirudin and nattokinase，and make positive contributions to the maintenance of human cardiovascular health.